Investors
Unique Opportunity: Acurex Right Now
Acurex is advancing its novel T-type selective calcium inhibitor, CU-00048, in Essential Tremor, where human target validation, a clearer regulatory path, short capital-efficient trials, major unmet need, and an estimated 7 million U.S. patients create a unique opportunity to unlock extraordinary value.
Acurex is seeking a high-quality lead investor for a pre-clinically valued Series A round, helping build Acurex through clinical proof-of-concept, and positioning the company for a strong Series B or a potential IPO. That is one path of value-building we believe CU-00048 can support.
We are open to explore other paths.
Acurex mirrors key elements seen in past breakthrough biotech success stories
CONTACT US REGARDING INVESTMENT OPPORTUNITIES:
Forward‑Looking Statement:
This communication contains forward‑looking statements, including statements about our research programs, development plans, future operations, and potential clinical or regulatory milestones. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Forward‑looking statements speak only as of the date made, and we undertake no obligation to update them except as required by law.